By the same authors

From the same journal

From the same journal

Model structuring for economic evaluations of new health technologies

Research output: Contribution to journalArticle

Standard

Model structuring for economic evaluations of new health technologies. / Haji Ali Afzali, Hossein; Bojke, Laura; Karnon, Johnathan.

In: Pharmacoeconomics., 20.07.2018.

Research output: Contribution to journalArticle

Harvard

Haji Ali Afzali, H, Bojke, L & Karnon, J 2018, 'Model structuring for economic evaluations of new health technologies', Pharmacoeconomics.. https://doi.org/10.1007/s40273-018-0693-7

APA

Haji Ali Afzali, H., Bojke, L., & Karnon, J. (2018). Model structuring for economic evaluations of new health technologies. Pharmacoeconomics.. https://doi.org/10.1007/s40273-018-0693-7

Vancouver

Haji Ali Afzali H, Bojke L, Karnon J. Model structuring for economic evaluations of new health technologies. Pharmacoeconomics. 2018 Jul 20. https://doi.org/10.1007/s40273-018-0693-7

Author

Haji Ali Afzali, Hossein ; Bojke, Laura ; Karnon, Johnathan. / Model structuring for economic evaluations of new health technologies. In: Pharmacoeconomics. 2018.

Bibtex - Download

@article{f9e1880ea3dd4cbeb8b921b533f84f5c,
title = "Model structuring for economic evaluations of new health technologies",
abstract = "In countries such as Australia, the UK and Canada, decisions on whether to fund new health technologies are commonly informed by decision analytic models. While the impact of making inappropriate structural choices/assumptions on model predictions is well noted, there is a lack of clarity about the definition of key structural aspects, the process of developing model structure (including the development of conceptual models) and uncertainty associated with the structuring process (structural uncertainty) in guidelines developed by national funding bodies. This forms the focus of this paper. Building on the reports of good modelling practice, and recognising the fundamental role of model structuring within the model development process, we specified key structural choices and provided ideas about the model structuring process for the future direction. This will help to further standardise guidelines developed by national funding bodies, with potential impact on transparency, comprehensiveness and consistency of model structuring. We argue that the process of model structuring and structural sensitivity analysis should be documented in a more systematic and transparent way in submissions to national funding bodies. Within the decision-making process, the development of conceptual models and presentation of all key structural choices would mean that national funding bodies could be more confident of maximising value for money when making public funding decisions",
author = "{Haji Ali Afzali}, Hossein and Laura Bojke and Johnathan Karnon",
note = "{\circledC} Springer Nature Switzerland AG 2018. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details",
year = "2018",
month = "7",
day = "20",
doi = "10.1007/s40273-018-0693-7",
language = "English",
journal = "Pharmacoeconomics.",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Model structuring for economic evaluations of new health technologies

AU - Haji Ali Afzali, Hossein

AU - Bojke, Laura

AU - Karnon, Johnathan

N1 - © Springer Nature Switzerland AG 2018. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

PY - 2018/7/20

Y1 - 2018/7/20

N2 - In countries such as Australia, the UK and Canada, decisions on whether to fund new health technologies are commonly informed by decision analytic models. While the impact of making inappropriate structural choices/assumptions on model predictions is well noted, there is a lack of clarity about the definition of key structural aspects, the process of developing model structure (including the development of conceptual models) and uncertainty associated with the structuring process (structural uncertainty) in guidelines developed by national funding bodies. This forms the focus of this paper. Building on the reports of good modelling practice, and recognising the fundamental role of model structuring within the model development process, we specified key structural choices and provided ideas about the model structuring process for the future direction. This will help to further standardise guidelines developed by national funding bodies, with potential impact on transparency, comprehensiveness and consistency of model structuring. We argue that the process of model structuring and structural sensitivity analysis should be documented in a more systematic and transparent way in submissions to national funding bodies. Within the decision-making process, the development of conceptual models and presentation of all key structural choices would mean that national funding bodies could be more confident of maximising value for money when making public funding decisions

AB - In countries such as Australia, the UK and Canada, decisions on whether to fund new health technologies are commonly informed by decision analytic models. While the impact of making inappropriate structural choices/assumptions on model predictions is well noted, there is a lack of clarity about the definition of key structural aspects, the process of developing model structure (including the development of conceptual models) and uncertainty associated with the structuring process (structural uncertainty) in guidelines developed by national funding bodies. This forms the focus of this paper. Building on the reports of good modelling practice, and recognising the fundamental role of model structuring within the model development process, we specified key structural choices and provided ideas about the model structuring process for the future direction. This will help to further standardise guidelines developed by national funding bodies, with potential impact on transparency, comprehensiveness and consistency of model structuring. We argue that the process of model structuring and structural sensitivity analysis should be documented in a more systematic and transparent way in submissions to national funding bodies. Within the decision-making process, the development of conceptual models and presentation of all key structural choices would mean that national funding bodies could be more confident of maximising value for money when making public funding decisions

U2 - 10.1007/s40273-018-0693-7

DO - 10.1007/s40273-018-0693-7

M3 - Article

JO - Pharmacoeconomics.

T2 - Pharmacoeconomics.

JF - Pharmacoeconomics.

ER -